Anti-sars-cov-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe covid-19: a randomized clinical trial

HIGHLIGHTS

  • who: Claudia M. Denkinger from the Laboratory have published the Article: Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial, in the Journal: (JOURNAL) of 16/09/2022
  • what: The results of this trial provide evidence that patients with cancer (group 1) who develop severe COVID-19 benefit from anti-SARS-CoV-2 plasma from convalescent/vaccinated donors and experience improved overall recovery. The trial was designed to enroll 174 patients (87 per arm) to detect a HR of 1 . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?